Literature DB >> 22490061

European ST80 community-associated methicillin-resistant Staphylococcus aureus orbital cellulitis in a neonate.

Evangelia E Tsironi1, Fani Zacharaki, Ioanna N Grivea, Sophia V Tachmitzi, Aspasia N Michoula, Marianna Vlychou, Efthimia Petinaki, George A Syrogiannopoulos.   

Abstract

BACKGROUND: Methicillin-resistant Staphylococcus aureus is a serious cause of morbidity and mortality in hospital environment, but also, lately, in the community. This case report is, to our knowledge, the first detailed description of a community-associated methicillin-resistant S. aureus ST80 orbital cellulitis in a previously healthy neonate. Possible predisposing factors of microbial acquisition and treatment selection are also discussed. CASE
PRESENTATION: A 28-day-old Caucasian boy was referred to our hospital with the diagnosis of right orbital cellulitis. His symptoms included right eye proptosis, periocular edema and redness. Empirical therapy of intravenous daptomycin, rifampin and ceftriaxone was initiated. The culture of pus yielded a methicillin-resistant S. aureus isolate and the molecular analysis revealed that it was a Panton-Valentine leukocidine-positive ST80 strain. The combination antimicrobial therapy was continued for 42 days and the infection was successfully controlled.
CONCLUSIONS: Clinicians should be aware that young infants, even without any predisposing condition, are susceptible to orbital cellulitis caused by community-associated methicillin-resistant S. aureus. Prompt initiation of the appropriate empirical therapy, according to the local epidemiology, should successfully address the infection, preventing ocular and systemic complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490061      PMCID: PMC3352026          DOI: 10.1186/1471-2415-12-7

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  11 in total

1.  Community-acquired methicillin-resistant Staphylococcus aureus in association with chronic dacryocystitis secondary to congenital nasolacrimal duct obstruction.

Authors:  Sylvia Kodsi
Journal:  J AAPOS       Date:  2006-12       Impact factor: 1.220

2.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

Review 3.  Community-acquired methicillin-resistant Staphylococcus aureus infections.

Authors:  Helen C Maltezou; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2006-01-19       Impact factor: 5.283

4.  Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates.

Authors:  Regine M Fortunov; Kristina G Hulten; Wendy A Hammerman; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

5.  Infantile orbital cellulitis secondary to community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Daisuke Kobayashi; Laurence B Givner; R Patrick Yeatts; Evelyn Y Anthony; Avinash K Shetty
Journal:  J AAPOS       Date:  2011-04-03       Impact factor: 1.220

6.  Nasal Staphylococcus aureus colonization among mothers of term and late preterm previously healthy neonates with community-acquired Staphylococcus aureus infections.

Authors:  Régine M Fortunov; Kristina G Hulten; Coburn H Allen; Wendy A Hammerman; Linda B Lamberth; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2011-01       Impact factor: 2.129

7.  Vertically acquired community methicillin-resistant Staphylococcus aureus dacryocystitis in a neonate.

Authors:  Tina Rutar
Journal:  J AAPOS       Date:  2008-10-18       Impact factor: 1.220

8.  Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.

Authors:  Regine M Fortunov; Kristina G Hulten; Wendy A Hammerman; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

9.  Daptomycin use in infants: report of two cases with peak and trough drug concentrations.

Authors:  M Cohen-Wolkowiez; P B Smith; D K Benjamin; V G Fowler; K C Wade
Journal:  J Perinatol       Date:  2008-03       Impact factor: 2.521

10.  Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece.

Authors:  George D Katopodis; Ioanna N Grivea; Angeliki J Tsantsaridou; Spyros Pournaras; Efi Petinaki; George A Syrogiannopoulos
Journal:  BMC Infect Dis       Date:  2010-12-13       Impact factor: 3.090

View more
  4 in total

1.  Neonatal orbital abscess.

Authors:  Pratik Y Gogri; Somen L Misra; Neeta S Misra; Hitesh V Gidwani; Akshay J Bhandari
Journal:  Oman J Ophthalmol       Date:  2015 May-Aug

Review 2.  Bacterial profile of ocular infections: a systematic review.

Authors:  Mebrahtu Teweldemedhin; Hailay Gebreyesus; Ataklti Hailu Atsbaha; Solomon Weldegebreal Asgedom; Muthupandian Saravanan
Journal:  BMC Ophthalmol       Date:  2017-11-25       Impact factor: 2.209

3.  Image-guided system endoscopic drainage of orbital abscess caused by methicillin-resistant Staphylococcus aureus in an infant.

Authors:  Tan Chai-Lee; Sanjeevan Nadarajah; Baharudin Abdullah; Irfan Mohamad; Thevagi Maruthamuthu; Chandran Nadarajan; Talib Norain; Ismail Shatriah
Journal:  Int J Surg Case Rep       Date:  2017-02-28

4.  Periorbital infections and conjunctivitis due to Panton-Valentine Leukocidin (PVL) positive Staphylococcus aureus in children.

Authors:  Pia-Alice Hoppe; Leif G Hanitsch; Rasmus Leistner; Michaela Niebank; Christoph Bührer; Horst von Bernuth; Renate Krüger
Journal:  BMC Infect Dis       Date:  2018-08-06       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.